The carbapenem antibiotics market size is expected to reach USD 5,346. 62 million by 2028 from $3,964. 57 million in 2021; it is estimated to grow at a CAGR of 4.4% from 2021 to 2028.
New York, March 17, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the publication of the report “Carbapenem-Based Antibiotics Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type, Indication, and Distribution Channel” – https://www.reportlinker.com/p06244542/?utm_source=GNW
Generic versions of antibiotics are popular due to their availability and affordability. Additionally, the expiration of patented carbapenem antibiotics has expanded the opportunities for generic drug manufacturers to enter the market with their profitable drugs.
The goal of generic drug producers is to increase the reach of these drugs. Moreover, the shortage of antibiotics to treat bacterial infections is also one of the major factors driving the market growth.
The increase in the production of generic carbapenem antibiotics has expanded the availability of the drugs in various low- and middle-income countries.
The generic versions of carbapenems available on the market are ertapenem (Invanz), imipenem/cilastatin (Primaxin IM), doripenem (Doribax) and meropenem (Merrem). Moreover, the growing number of generic players in the market is accelerating the production of generic drugs.
Many Asian companies are engaged in the development of active pharmaceutical ingredients (APIs), which are needed to produce generic carbapenem antibiotics. in the USA.
The company plans to enter the global carbapenem antibiotic market in the coming years. It has also successfully developed its technology independently in Korea to produce Doripenem.
In addition, the company plans to expand IPA and finished drug sales of Imipenem and Meropenem by exporting them to more than 40 countries, including China and Japan. As a result, the companies are accelerating the production of generic drugs and driving the growth of the global carbapenem antibiotics market.
Based on type, the carbapenem antibiotics market is segmented into meropenem, doripenem, imipenem, tebipenem and others. The others segment held the largest market share of the carbapenem antibiotics market in 2021, and it is expected to register the highest CAGR. in the carbapenem antibiotics market over the forecast period.
The growing developments of carbapenem antibiotics are expected to drive the market growth in the future.
Based on indications, the carbapenem antibiotics market is segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections and others. The others segment held the largest carbapenem antibiotics market share in 2021 and is estimated to register the highest CAGR in the market during the forecast period.
By distribution channel, the carbapenem antibiotics market is segmented into retail pharmacies, online pharmacies and hospital pharmacies. The hospital pharmacy segment held the largest carbapenem antibiotics market share in 2021, and is estimated to register the highest CAGR in the market during the forecast period.
Based on geography, the carbapenem antibiotics market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America. years.
The region is expected to experience steady growth in the future due to factors such as increased adoption of carbapenem antibiotics, high rate of antibiotic prescribing, and progress in research and development leading to the emergence and launch of new drugs. However, the market in Asia-Pacific is expected to witness the fastest growth in the coming years.
The market size of carbapenem antibiotics in India and China is expected to grow rapidly due to factors such as large population, growing interest of market players in developing new vaccines and products at affordable prices, and the high penetration of market players manufacturing generic drugs and exporting them across the world.
World Health Organization (WHO), Food and Drug Administration (FDA), Saudi Clinical Trials Registry, National Institute of Health, Ministry of Health and Prevention, and Centers for Disease Control and Prevention (CDC) are among the primary and secondary sources referred during the preparation of the global Carbapenem Antibiotics Market report.
Read the full report: https://www.reportlinker.com/p06244542/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001